While it's encouraging that another HIV drug company is offering medicine at a more affordable price, private healthcare needs to be revisited.

Without policy measures that regulate how much drug companies can charge for their drugs or stricter patent laws that prevent companies from re-copyrighting old drugs, there is little to avert drug price hikes.